Materials and methods for preventing and treating microbe-mediated epithelial disorders

Patent metadata

Field	Value
Publication number	US-2016129038-A1
Application number	US-201514936088-A
Country	US
Kind code	A1
Filing date	Nov 9, 2015
Priority date	Nov 26, 2002
Publication date	May 12, 2016
Grant date	—

Abstract

The present invention provides pharmaceutical compositions in the form of relatively high molecular weight biocompatible polymers such as polyethylene glycol, optionally supplemented with a protective polymer such as dextran and/or essential pathogen nutrients such as L-glutamine. Also provided are methods for preventing or treating gut-derived sepsis attributable to intestinal pathogens such as Pseudomonas aeruginosa by administering high molecular weight polyethylene glycol as well as methods for monitoring the administration of high molecular weight polyethylene glycol, such as in methods of preventing, ameliorating or treating microbe-induced epithelial disorders, as exemplified by gut-derived sepsis. Frequently, gut-derived sepsis arises as a complication in mammals recovering from surgical intervention or suffering from a disease or disorder, providing indications of suitable animals to receive preventative treatment. Finally, the invention provides a composition comprising infant formula and polyethylene glycol and methods for using that composition.

First claim

1 .- 75 . (canceled)

76 . A method of treating a microbe-mediated disorder in an animal, the microbe selected from the group consisting of Escherichia coli , Clostridium, Pseudomonas aeruginosa, Enterobacteria cloacae, Serratia marcescens, Klebsiella oxytocia, Candida albicans, Candida globrata , and Bacillus anthracis , the method comprising:
administering to the animal a composition comprising polyethylene glycol (PEG), wherein the PEG has an average molecular weight of at least 12,000 daltons and comprises a plurality of PEG molecules joined with a phenol linker.

77 . The method according to claim 76 wherein the PEG has an average molecular weight of at least 15,000 daltons.

78 . The method according to claim 76 wherein the PEG has an average molecular weight of between about 15,000 and 20,000 daltons.

79 . The method according to claim 76 wherein the PEG is in an aqueous solution comprising 5-20% PEG.

80 . The method according to claim 79 wherein the aqueous solution comprises 10% PEG.

81 . The method according to claim 76 , wherein the composition further comprises a vehicle selected from the group consisting of a liquid solution, a topical gel, and a solution suitable for nebulizing.

82 . The method according to claim 76 further comprising introducing an effective amount of a compound selected from the group consisting of dextran, dextran-coated L-glutamine and dextran-coated inulin into the intestine of the animal.

83 . The method according to claim 76 further comprising introducing an effective amount of L-glutamine into the intestine of the animal.

84 . The method according to claim 76 wherein the animal is selected from the group consisting of dog, cat, sheep, goat, cow, pig, chicken, horse and human.

85 . The method according to claim 84 wherein the animal is human.

86 . A method of treating an animal suffering from gut-derived sepsis, enteropathy, burn injury, severe neutropenia, swimmer's ear, acute otitis media, chronic otitis media, ventilator-associated pneumonia, necrotizing enterocolitis, antibiotic-induced diarrhea, pseudomembranous colitis, irritable bowel disease, neutropenic enterocolitis, neonatal enterocolitis, pancreatitis, chronic fatigue syndrome, dysbiosis syndrome, microscopic colitis, or a chronic urinary tract infection, the method comprising:
administering to the animal a composition comprising polyethylene glycol (PEG), wherein the PEG has an average molecular weight of at least 12,000 daltons and comprises a plurality of PEG molecules joined with a phenol linker.

87 . The method according to claim 86 wherein the PEG has an average molecular weight of at least 15,000 daltons.

88 . The method according to claim 86 wherein the PEG has an average molecular weight of between about 15,000 and 20,000 daltons.

89 . The method according to claim 86 wherein the PEG is in an aqueous solution comprising 5-20% PEG.

90 . The method according to claim 89 wherein the aqueous solution comprises 10% PEG.

91 . The method according to claim 86 , wherein the composition further comprises a vehicle selected from the group consisting of a liquid solution, a topical gel, and a solution suitable for nebulizing.

92 . The method according to claim 86 further comprising introducing an effective amount of a compound selected from the group consisting of dextran, dextran-coated L-glutamine and dextran-coated inulin into the intestine of the animal.

93 . The method according to claim 86 further comprising introducing an effective amount of L-glutamine into the intestine of the animal.

94 . The method according to claim 86 wherein the animal is selected from the group consisting of dog, cat, sheep, goat, cow, pig, chicken, horse and human.

95 . The method according to claim 94 wherein the animal is human.

Assignees

• Univ Chicago

Inventors

• Alverdy John C

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P31/10

  Antimycotics · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P27/16

  Otologicals · CPC title